Suchen
Immatics NV
IMTXZur Watchlist hinzufügen
8.240USD
-0.360-4.19%
Trading geöffnet 09/24, 12:44（ET）
1.13BMarktkapitalisierung
VerlustKGV TTM
Über Immatics NV Unternehmen
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Immatics NV Profil
BörsenkürzelIMTX
Name des UnternehmensImmatics NV
IPO-datumJul 02, 2020
CEOSingh (Harpreet)
Anzahl der mitarbeiter297
WertpapierartOrdinary Share
GeschäftsjahresendeJul 02
AddressePaul Ehrlich-Strasse 15
StadtTUEBINGEN
BörseNASDAQ OMX - NASDAQ BASIC
LandGermany
Postleitzahl72076
Telefon4970715397700
Websitehttps://immatics.com/
BörsenkürzelIMTX
IPO-datumJul 02, 2020
CEOSingh (Harpreet)
Führungskräfte von Immatics NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
502.83K
+24.29%
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
502.83K
+24.29%
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
502.83K
+24.29%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
394.52K
+10.14%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
394.52K
+10.14%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
394.52K
+10.14%
Mr. Jordan Silverstein
Mr. Jordan Silverstein
Head of Strategy
Head of Strategy
384.98K
+26.63%
Mr. Jordan Silverstein
Mr. Jordan Silverstein
Head of Strategy
Head of Strategy
384.98K
+26.63%
Mr. Jordan Silverstein
Mr. Jordan Silverstein
Head of Strategy
Head of Strategy
384.98K
+26.63%
Mr. Edward Sturchio, J.D.
Mr. Edward Sturchio, J.D.
General Counsel
General Counsel
300.63K
+33.47%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
502.83K
+24.29%
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
502.83K
+24.29%
Dr. Steffen Walter, Ph.D.
Dr. Steffen Walter, Ph.D.
Chief Operating Officer
Chief Operating Officer
502.83K
+24.29%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
394.52K
+10.14%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
394.52K
+10.14%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Non-Executive Director
Non-Executive Director
394.52K
+10.14%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Immatics NV?
Die fünf größten Anteilseigner von Immatics NV sind: Dr. Steffen Walter, Ph.D.
Wie viele Institutionen halten Anteile an Immatics NV (IMTX)?
Mit Stand vom 2026Q1 halten 191 Institutionen Anteile an Immatics NV, mit einem Gesamtmarktwert von etwa 101.84M, was 75.94% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -17425391.00 gestiegen.